Lipella Pharmaceuticals Inc.
LIPO
$0.03
Change (1 day)
$2.71
Year High
$0.32
Year Low
Categories
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Lipella Pharmaceuticals Inc. (LIPO) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 32.29 K | -3,157,144 | 432.73 K | 3.58 M | 3.43 M |
| 2022 | 113.66 K | -4,692,223 | 1.27 M | 5.95 M | 5.8 M |
| 2021 | -1,130,867 | 589.34 K | 2.01 M | 1.81 M | |
| 2020 | 69.04 K | -217,824 | 491.7 K | 955.02 K | 699.43 K |
| 2019 | 83.89 K | 74 K | 237.26 K | 118.92 K | 118.92 K |